Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Cephalon
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT01029730
First received: December 8, 2009
Last updated: April 9, 2014
Last verified: April 2014

December 8, 2009
April 9, 2014
January 2010
December 2014   (final data collection date for primary outcome measure)
To determine the complete response rate in patients with previously untreated low grade lymphoma following treatment with bendamustine/bortezomib/rituximab. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01029730 on ClinicalTrials.gov Archive Site
  • To assess overall response rate (ORR) in patients with previously untreated low grade lymphoma following treatment with bendamustine/bortezomib/rituximab. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To assess progression-free survival (PFS) of patients with previously untreated low grade lymphoma following treatment with bendamustine/bortezomib/rituximab. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To characterize the toxicity of bendamustine/bortezomib/rituximab in patients with previously untreated low grade lymphoma. [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

The goal of this Phase II study is to add bortezomib to the highly active regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a weekly schedule (Days 1, 8, 15) and will be added to bendamustine/rituximab given in 4-week cycles. This combination uses the standard bendamustine dosing schedule, and is more convenient than the 5-week regimen of these 3 drugs currently being studied. This trial will be conducted at multiple study sites by the Sarah Cannon Research Institute (SCRI) Oncology Research Consortium.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lymphoma
  • Drug: Bendamustine
    Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
    Other Name: TREANDA®
  • Drug: Bortezomib
    Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
    Other Name: VELCADE®
  • Drug: Rituximab
    Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
    Other Name: Rituxan®
Experimental: 1
Bendamustine, Bortezomib, and Rituximab
Interventions:
  • Drug: Bendamustine
  • Drug: Bortezomib
  • Drug: Rituximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
55
June 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically-confirmed indolent lymphoma by the World Health Organization (WHO) classification. The biopsy must fulfill one of the following criteria:

    • Follicular lymphoma, grade 1 or 2
    • Marginal zone lymphoma
    • Small lymphocytic lymphoma (circulating lymphocyte count must be <5,000)
    • Lymphoplasmacytic lymphoma
  2. At least one of the following criteria must be met:

    • Presence of any symptoms related to lymphoma. These can include classic B-symptoms (fever [>38°C] of unclear etiology, night sweats, weight loss of greater than 10% within the prior 6 months) or other lymphoma-related symptoms (fatigue, pain, etc.).
    • Large tumor mass (bulky disease) characterized by lymphomas with a diameter of more than 3 cm in three or more regions or by a lymphoma with a diameter >7 cm in one region
    • Presence of lymphoma-related complications, including narrowing of ureters or bile ducts, tumor-related compression of a vital organ, lymphoma-induced pain, cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or ascites
    • Hyperviscosity syndrome due to monoclonal gammopathy
  3. The lymph node biopsy or other lymphoma pathology specimen has CD20+ B-cells.
  4. Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease.
  5. No previous systemic treatment for lymphoma. Patients may have had a single course of radiation therapy to a limited field (i.e., not exceeding two adjacent lymph node regions).
  6. The patient has bidimensionally measurable disease with at least 1 lesion measuring ≥2.0 cm in a single dimension, and the field was not previously radiated.
  7. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
  8. Adequate hematologic function ≤7 days prior to start of study treatment:

    • Hemoglobin ≥10.0 g/dl
    • Absolute neutrophil count (ANC) ≥1000/µL
    • Platelet count ≥75,000/µL. If low counts are attributable to bone marrow infiltration or hypersplenism due to lymphoma, ANC must be ≥750/µL and platelets ≥50,000/µL.
  9. Calculated or measured creatinine clearance ≥30 mL/min ≤7 days of study enrollment (using Cockcroft-Gault method).
  10. Adequate hepatic function (≤2.5 x upper limit of normal [ULN] for alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase and total bilirubin within normal limits).
  11. Patients must be ≥18 years of age.
  12. Women of childbearing potential must agree to use a medically acceptable method of birth control (e.g., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 12 months after their last dose of rituximab. Men must use an acceptable method/form of contraception for the duration of treatment and for 3 months after the end of treatment.
  13. Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.

Exclusion Criteria:

  1. The patient has chronic lymphocytic leukemia.
  2. The patient has transformed lymphoma.
  3. History of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma.
  4. The patient has received corticosteroids for treatment of lymphoma. Chronic, low-dose corticosteroids (e.g., prednisone ≤20 mg/day) are allowed for treatment uses other than lymphoma or complications of lymphoma.
  5. Peripheral neuropathy ≥ CTCAE v3.0 grade 2, ≤14 days of study enrollment.
  6. Myocardial infarction ≤6 months prior to study enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, ECG abnormalities at screening must be documented as not medically relevant.
  7. History of solid organ transplantation, or post-transplant lymphoproliferative disorder.
  8. Patients with known history of hepatitis B or hepatitis C infection. Hepatitis B surface antigen must be tested.
  9. The patient has known human immunodeficiency virus (HIV) infection.
  10. Active, clinically serious infection > grade 2. Patients may be eligible upon resolution of the infection.
  11. Female patient is pregnant or breast-feeding. Confirmation that female patients of childbearing potential are not pregnant must be established by a negative serum pregnancy test ≤7 days prior to the start of treatment.
  12. Known hypersensitivity to bendamustine, bortezomib, boron, mannitol, or rituximab.
  13. Concomitant active malignancy requiring therapy.
  14. Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  15. Treatment with other investigational agents ≤14 days prior to study enrollment.
  16. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition, that contraindicates the use of study drugs, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient inappropriate for this study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01029730
SCRI LYM 66
No
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
  • Millennium Pharmaceuticals, Inc.
  • Cephalon
Study Chair: Ian W. Flinn, MD, PhD SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP